Comorbidities in Multiple Myeloma
|
|
- Hubert Sanders
- 6 years ago
- Views:
Transcription
1 Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014
2
3 Disclosures Advisory board: Janssen, Celgene Speaker s honoraria: Janssen, Celgene, Novartis 3
4 Male patient, 76 y Medical history: arterial hypertension total knee replacement Medication: amlodipine 5 mg/d Current problem: newly diagnosed MM, IgG kappa CRAB: anemia, pathological rib fracture Patient is active and independent Which treatment would you prefer: 1. VMP twice weekly 2. VMP weekly 3. VMPT 4. MPT 5. Lenalidomide-dexamethasone
5 Male patient, 72 y Medical history: coronary bypass COPD GOLD II chronic atrial fibrillation Medication: dabigatran, atenolol, perindopril Current problem: newly diagnosed MM, IgG kappa CRAB: anemia, pathological vertebral fracture Patient has mild/moderate dyspnea Which treatment would you prefer: 1. VMP twice weekly 2. VMP weekly 3. VMPT 4. MPT 5. Lenalidomide-dexamethasone
6 Treatment optimization Aim: to deliver effective treatment without excessive toxicity Efficacy Toxicity Risk of undertreatment: early relapse Risk of overtreatment: early treatment discontinuation
7 Comorbidities It is the concurrent presence of two or more medically diagnosed diseases in the same individual, with the diagnosis of each contributing disease based on established, widely recognized criteria. between 65 and 80y: one third has at least one comorbidity 80 y: up to 70% of the population has at least one comorbidity men women Fried et al, J Gerontol 2004;59:255
8 Type of comorbidities Chronic diseases mental illness cardiac disease (e.g. cardiac failure, arhytmia) chronic respiratory disease (e,g, COPD) hepatic disease kidney disorders (e.g. renal insufficiency) diabetes vascular disease musculoskeletal disorders peripheral nerve disorders acute intercurrent diseases another invasive malignancy * examples for multiple myeloma
9 disease-related adverse events as comorbidities pathological fracture, spinal cord compression, hypercalcemia renal failure infection
10 Treatment-related adverse events More treatment discontinuation in patients > 75y Palumbo et al, Blood 2011;118:4519
11 Impact of cardiac, infective and gastrointestinal AEs on survival All patients Treatment subgroups HR (95% CI ) P value n = 1435 All 2.53 (1.75 to 3.64) <0.001 MP 1.46 (0.59 to 3.63) 0.41 MPT 2.96 (1.71 to 5.15) <0.001 VMP 2.73 (1.03 to 7.24) 0.04 VMPT/VTP 2.77 (1.18 to 6.51) , Higher mortality in patients without cardiac, infective or GI AEs Higher mortality in patients with cardiac, infective or GI AEs Bringhen et al. Haematologica 2013;98:980
12 Aiming too high in the very elderly MPR a MP Discontinuation rate b years of age 17% 10% > 75 years of age 34% 16% Cumulative dose intensity c years of age 88% 97% > 75 years of age 56% 97% a MPR includes MPR-R and MPR for the initial 9 cycles. b Discontinuation due to AEs or withdrawal of consent c Cumulative dose intensity of melphalan and lenalidomide/placebo Palumbo A, et al. Blood. 2010;116: Abstract 622.
13 How to assess comorbidities? Clinical judgement driven by clinical experience Pro: fast Con: measurement can be time- and circumstance-dependent Global scores for health assessment: Karnofsky Performance Status ECOG/WHO score Specific scores: for transplant candidates: HCT-CI (Charlson, Sorror) for non-transplant candidates: comprehensive geriatric assessment (cga)
14 Scores for overall health evaluation ECOG/0WHO/Zubrod performance score Score Description 0 asymptomatic (Fully active, able to carry on all predisease activities without restriction) 1 Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work) 2 Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours) 3 Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours) 4 Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair) 5 death
15 Scores for overall health evaluation Karnofsky Performance Score Score Description 100% normal, no complaints or signs of disease 90% normal activity, few symptoms or signs 80% normal activity with some difficulty, symptoms or signs 70% caring for self, not capable of normal activity or work 60% requires some help, can take care of most personal requirements 50% requires help often, requires frequent medical care 40% disabled, requires special care and help 30% severely disabled, hospital admission indicated but no risk of death 20% very ill, urgently requiring admission, requires supportive measurements or treatment 10% moribund, rapidly progressive fatal disease process 0% death Karnofsky DA et al. 1949
16 Specific comorbidity scores for myeloma n = 466 MM patients comorbidities measured: Karnofsky Performance Scale kidney function (egfr) respiratory function (FEV1/FVC) Kleber et al. Clin Myeloma, Lymphoma & Leukemia 2013;13:541
17 Specific comorbidity scores for myeloma combination with ISS and age Kleber et al. Clin Myeloma, Lymphoma & Leukemia 2013;13:541
18 Disability Disability is defined as difficulty or dependency in carrying out activities essential to independent living, including essential roles, tasks needed for self-care and living independently in a home, and desired activities important to one s quality of life Disability can be measured with: -ADL*: e.g. dressing, eating, bathing, -IADL**: e.g. using a phone, preparing a meal, *ADL: activities of daily living **IADL: instrumental activities of daily living Fried et al, J Gerontol 2004;59:255
19 Frailty Frailty can be defined as a physiologic state of increased vulnerability to stressors that results from decreased physiologic reserves, and even dysregulation, of multiple physiologic systems. Clinical symptoms are: weakness, low physical activity, weight loss, poor endurance, slow gait speed 1 Kaplan Meier probability of survival over 12 years, according to baseline health status, for persons 70 years or older (D). 1.Fried et al, J Gerontol 2004;59:255 Rockwood et al. CMAJ DOI: /cmaj Palumbo et al, Blood 2011;118(17):
20 Overlap between comorbidity, frailty, disability Disability Comorbidity 21% 5.7% 46% 27% Frailty Data from the Cardiovascular Health Study (n = 2762 participants > 65y) Fried et al, J Gerontol Med Sci 2001;56A: M146
21 Frail patients with comorbidities are underrepresented in clinical trials (n = 85 clinical trials) The main finding from our study is that older patients are still commonly excluded from clinical trials on hematologic malignancies,,,, Cherubini et al. Haematologica 2013;98:997
22 Multiple myeloma is primarily a disease of the elderly patient patiens (%)
23 An intuitive approach for vulnerable MM patiens Risk factors age over 75 y mild, moderate or severe frailty comorbidities: cardiac/pulmonary/hepatic/renal dysfunction GO-GO MODERATE-GO SLOW-GO no risk factors at least one risk factor at least one risk factor plus occurence of grade 3-4 non-hematol. AE Dose level 0 Dose level - 1 Dose level - 2 Palumbo et al, Blood 2011;118(17):
24 Dose and regimen adjustment according to vulnerability DOSE LEVEL 0 DOSE LEVEL 1 DOSE LEVEL 2 Lenalidomide 25 mg/d d 1-21 / 4 wks 15 mg/d d 1-21 / 4 wks 10 mg/d d 1-21 / 4 wks Thalidomide 100 mg/d 50 mg/d 50 mg/every other day Bortezomib 1.3 mg/m 2 d 1,8,15,22 / 5 wks 1.0 mg/m 2 d 1,8,15,22 / 5 wks 1.3 mg/m 2 d 1,15 / 4 wks Melphalan 0.2 mg/kg/d d 1-4 / 5 wks 0.15 mg/kg d 1-4 / 5 wks 0.10 mg/kg d 1-4 / 5 wks Prednisone 2 mg/kg/d d 1-4 / 5 wks 1.5 mg/kg/d d 1-4 / 5 wks 1 mg/kg/d d 1-4 / 5 wks Palumbo et al N Engl J Med. 2011;364:1046
25 Comprehensive geriatric assessment Functionality: ADL IADL Falls Fatigue: MOB-T Pain: VAS score Mental health: MMSE GDS-4 Nutritional status: MNA-SF Social Status ADL: Activities of Daily Living; IADL: Instrumental Activities of Daily Living, MOB-T: Mobility-Tiredness Test: MMSE: Mini-Mental Status Examination; GDS: Geriatric Depression Score; MNA: Mini-Nutritional Assessment Short Form; VAS: Visual Analogue Scale Kenis et al. Ann Oncol 2013;24:1307
26 n = 1967 cancer patients 70% had a geriatric risk profile (G8 score) in 62% physicians were aware of the geriatric assessment In 52% GA detected unknown geriatric problems In 26% this resulted in a specific geriatric intervention In 25% GA influenced anti-tumoral treatment decision Kenis et al. Ann Oncol 2013;24:1307
27 Larocca et al. ASH 2013 (Abstract 687), oral presentation
28 Larocca et al. ASH 2013 (Abstract 687), oral presentation
29 Larocca et al. ASH 2013 (Abstract 687), oral presentation
30 Larocca et al. ASH 2013 (Abstract 687), oral presentation
31 Larocca et al. ASH 2013 (Abstract 687), oral presentation
32 Larocca et al. ASH 2013 (Abstract 687), oral presentation
33 Larocca et al. ASH 2013 (Abstract 687), oral presentation
34 Overall conclusions Patient-specific characteristics (comorbidities, disability, frailty) should be included in treatment decision A comprehensive geriatric assessment is recommended in the (very) elderly MM patients Patient vulnerability affects treatment adverse events, treatment duration and progressionfree and overall survival Risk-adapted treatment can improve the outcome of the vulnerable MM patient
35 Future: specific biomarkers for aging? Pallis et al. J Geriat Oncol 2014;5:84
36
Risk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationGeriatrics and Cancer Care
Geriatrics and Cancer Care Roger Wong, BMSc, MD, FRCPC, FACP Postgraduate Dean of Medical Education Clinical Professor, Division of Geriatric Medicine UBC Faculty of Medicine Disclosure No competing interests
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationDisclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationFrailty Assessment: Simplifying the Complex
Frailty Assessment: Simplifying the Complex Natalie Sanders, DO Internal Medicine, Geriatrics Rocky Mountain Geriatrics Conference 2017 U N I V E R S I T Y O F U T A H H E A L T H, 2 0 1 7 OBJECTIVES Define
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationDr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India
IMPORTANCE OF COMPREHENSIVE GERIATRIC ASSESSMENT IN CANCER IN ELDERLY AN INDIAN PERSPECTIVE Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India INTRODUCTION - Cancer in
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationCancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka
Cancer Treatment in the Elderly Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Patients 65 and older are the fastest growing segment of the US population By 2030, it will comprise
More informationGeriatric screening tools in older patients with cancer
Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationProspective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease
Prospective Evaluation of the Eyeball Test for Assessing Frailty in Elderly Patients with Valvular Heart Disease Background Frailty is a common occurrence in elderly patients Approximately half of the
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationMultiple Myeloma in the Elderly: When to Treat, When to Go to Transplant
Multiple Myeloma in the Elderly: When to Treat, When to Go to Transplant Review Article [1] October 15, 2010 By Jean-luc Harousseau, MD [2] Until recently, standard treatment of multiple myeloma (MM) in
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationMayo Clinic, Rochester, Minnesota; 2 Tufts Medical Center, Boston, Massachusetts; 3
NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Final Results From a Phase 1/2 Study Morie A. Gertz, 1 Raymond L. Comenzo, 2 Heather
More informationAssessing older patients with hematological malignancies
Assessing older patients with hematological malignancies Alfonso J. Cruz Jentoft Servicio de Geriatría Hospital Universitario Ramón y Cajal Madrid, Spain Is old = frail? 45 days old 2,000 years old 4,600
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationNew Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic)
New Approaches to Evaluate And Optimize Older Patients for Transplant (Allogeneic) Andrew S. Artz, MD, MS Associate Professor of Medicine Clinical Director, Hematopoietic Cellular Therapy Program University
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationSCALES SCALES SCALES. Performance Scales WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? KPS FAST ECOG PPS NYHA MRI ALSFRS
SCALES SCALES SCALES WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? Karen L. Cross, MD, FAAHPM Performance Scales KPS FAST ECOG PPS NYHA MRI ALSFRS PPS = 30, 40, or 50 ECOG = 2, 3, or 4 NYHA
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationIntegrating Frailty Screening for Older Patients Diagnosed with Multiple Myeloma
Integrating Frailty Screening for Older Patients Diagnosed with Multiple Myeloma Target Audience This activity has been designed to meet the educational needs of hematologists, medical oncologists, physician
More informationINTEGRATED GERIATRIC AND PRIMARY CARE MANAGEMENT OF FRAIL OLDER ADULTS IN THE COMMUNITY
INTEGRATED GERIATRIC AND PRIMARY CARE MANAGEMENT OF FRAIL OLDER ADULTS IN THE COMMUNITY LM Pérez (1), P Burbano (1), M Hernandez (1), N Gual (1,2), G Liesa (1), E Martin (3), L Tobella (3), MB Enfedaque
More informationHEART INTERVENTIONS IN OLDER PATIENTS. FILTERING FOR FRAILTY.
HEART INTERVENTIONS IN OLDER PATIENTS. FILTERING FOR FRAILTY. December 8, 2017 Allen R. Huang, MDCM, FRCPC, FACP 1 Faculty Disclosure Faculty: Allen Huang MDCM, FRCPC, FACP Associate Professor, University
More informationComorbidities and cancer Applications to non small cell lung cancer
Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1 Comorbidities and cancer Why? 2 Epidemiology elderly among lung cancer 2010-2014
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 24 July 2003 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION
More informationPre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014
Pre- Cardiac intervention Frailty assessment Dr. Victor Sim 26 th Sept 2014 Defining frailty Lacks consensus (Rockwood CMAJ 2005;173(5):489-95 Introduction) Some consider symptoms, signs, diseases and
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationMyeloma care and proteasome inhibitors. Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania
Myeloma care and proteasome inhibitors Brendan M. Weiss, MD Abramson Cancer Center University of Pennsylvania Why care about CV toxicities in MM? Median age 72 years About 2/3 have CV disease at baseline
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationDefinitions in Palliative Care
Definitions in Palliative Care Palliative care is specialist care provided for all people living with, and dying from a terminal condition and for whom the primary goal is quality of life. Palliative Care
More informationComprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies
BHSSeminar#7 Generalskills Comprehensive Geriatric Assesment (CGA) In Older Patients with Malignant Hemopathies Prof.&&&Dominique&&BRON& Inst.&J.&Bordet&&7&ULB& 24th&of&May&2014& 1 WHY WHEN HOW WhyCGA?!
More informationDRAFT FOR PUBLIC CONSULTATION
SEE MYELOMA ELIGIBLE egfr < 30ml/min Multiple myeloma despite correction of hypercalcaemia and dexamethasone? Yes Transplant eligible? Yes SEE MYELOMA- RENAL SEE MYELOMA INELIGIBLE KEY Click to move to
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationOld age, polymorbidity and stroke, a new epidemy?
Old age, polymorbidity and stroke, a new epidemy? Professor Gary Ford Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals Visiting Professor
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationFrailty as deficit accumulation
Frailty as deficit accumulation Kenneth Rockwood MD, FRCPC, FRCP Division of Geriatric Medicine Dalhousie University & Capital District Health Authority Halifax, Canada Read it as: Rockwood K, Mitnitski
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationwhich to base economic assessment of the products available to treat this hematologic
special feature Measuring Value of Multiple Myeloma Therapies by Gary M. Owens, MD, Gary Owens Associates As recent therapies for multiple myeloma (MM) have provided significant improvements in the prognosis
More informationBackground Information
What is Velcade (bortezomib)? Velcade (bortezomib) is a medicine used to treat a blood cancer known as multiple myeloma, and was the first of the treatments in the class of anti-cancer drugs known as proteasome
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationFrailty: Challenges and Possible Solutions
Frailty: Challenges and Possible Solutions EMA Workshop: Ensuring safe and effective medicines for an ageing population Niccolò Marchionni Professor of Geriatrics University of Florence, Italy 22-23 March
More informationProblems related to the management of malignant hemopathies in older patients
Problems related to the management of malignant hemopathies in older patients Dr Marie Maerevoet Gent, 25 January 2013 BHS satellite symposium on Elderly Malignant Hemopathies in older patients - 33% of
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationPractical Considerations in Multiple Myeloma: Optimizing Therapy With New Proteasome Inhibitors
Welcome to Managing Myeloma. My name is Dr. Donald Harvey. I am Director of Phase 1 Clinical Trials Section and an Associate Professor in Hematology, Medical Oncology, and Pharmacology at the Winship Cancer
More informationInterprofessional Care for Elders through 48/5
Interprofessional Care for Elders through 48/5 Janet E. McElhaney, MD, FRCPC, FACP HSN Volunteer Association Chair in Geriatric Research Professor of Medicine, Northern Ontario School of Medicine Health
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationUnintentional Weight Loss. Prof. G. Zuliani
Unintentional Weight Loss Prof. G. Zuliani Is weight loss clinically important? Definition Clinically important weight loss can be defined as loss of >5 kg, or >5% of usual weight over a period of 3 months,
More informationFrailty in Older Adults
Frailty in Older Adults John Puxty puxtyj@providencecare Geriatrics 20/20: Bringing Current Issues into Perspective Session Overview Definition of Frailty Strategies for identifying frail older adults
More informationSpecialist Palliative Care Service Referral Criteria and Guidance
Specialist Palliative Care Service Referral Criteria and Guidance Specialist Palliative Care Service Referrals These guidelines cover referrals for patients with progressive terminal illness, whether
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationBiological theory for the construct of intrinsic capacity to be used in clinical settings Matteo Cesari, MD, PhD
Biological theory for the construct of intrinsic capacity to be used in clinical settings Matteo Cesari, MD, PhD World Health Organization Geneva (Switzerland) December 1, 2016 World Health Organization.
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma October 1, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma October 1, 2015 DISCLAIMER Not a Substitute for Professional Advice This
More informationCommunity and Mental Health Services. Palliative Care. Criteria and
Community and Mental Health Services Specialist Palliative Care Service Referral Criteria and Guidance November 2018 Specialist Palliative Care Service Referrals These guidelines cover referrals for patients
More informationThe Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly
ORIGINAL ARTICLE Korean J Intern Med 2016;31:594-600 The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly Hee-Won Jung 1,2, Hyun-Jung
More informationIntegrating Geriatrics into Oncology Care
Integrating Geriatrics into Oncology Care William Dale, MD, PhD Chief, Geriatrics & Palliative Medicine Director, Specialized Oncology Care & Research in the Elderly (SOCARE) Clinic University of Chicago
More informationNutritional Assessment in frail elderly. M. Secher, G.Abellan Van Kan, B.Vellas 1st December 2010 Firenze
Nutritional Assessment in frail elderly M. Secher, G.Abellan Van Kan, B.Vellas 1st December 2010 Firenze Frailty definition Undernutrition as part of the frailty syndrome Nutritional assessment in frail
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationAHFS Final. Criteria Used in. Strength. Grade of. hydrochloride. per day on 12, and mg/m 2 IV. Strength. Grade of. Bortezomib 1.
AHFS Final Determination of Medical Acceptance: Off-label Use of Bortezomib in Combination with Doxorubicin and Dexamethasone as Inductionn Therapy for Newly Diagnosed Multiple Myeloma in Transplant-eligible
More informationMultiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015
Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the
More informationFrailty. Nicholas Butler MD, MBA Department of Family Medicine University of Iowa
Frailty Nicholas Butler MD, MBA Department of Family Medicine University of Iowa Doris 84 yo female who comes into your clinic with her daughter. She complains of feeling increasingly fatigued and just
More informationSpecialist Palliative Care Referral for Patients
Specialist Palliative Care Referral for Patients This guideline covers referrals for patients with progressive terminal illness, whether due to cancer or other disease. For many patients in the late stages
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationThe role of liposomal doxorubicin in DLBCL lymphomas. Michele Spina Aviano
The role of liposomal doxorubicin in DLBCL lymphomas Michele Spina Aviano Disclosures of Michele Spina Company name Research support Employee Consultant Stockholder Speakers bureau Advisory board Other
More informationWhat is frailty and why it is important
What is frailty and why it is important Tony Moran North West Knowledge and Intelligence Team Cancer Outcomes Conference 2013 Contents Definitions of frail and frailty Prevalence and measurement Use in
More informationWelcome to the Routine frailty identification in the GP contract webinar presented by Dawn Moody
Welcome to the Routine frailty identification in the GP contract webinar presented by Dawn Moody The presentation will begin at 12.00pm. Attendees will be muted during the presentation to avoid interference.
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationFRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger
FRAILTY SYNDROME dr. Rose Dinda Martini, Sp.PD, K-Ger Geriatric Division, Internal Medicine Department M. Djamil Hospital Padang Faculty of Medicine, Andalas University, 2018 Medical syndrome Multiple
More informationFrailty as deficit accumulation
Frailty as deficit accumulation Kenneth Rockwood MD, FRCPC, FRCP Division of Geriatric Medicine Dalhousie University & Capital District Health Authority Halifax, Canada Read it as: Rockwood K, Mitnitski
More information